Review





Similar Products

cd80  (Miltenyi Biotec)
94
Miltenyi Biotec cd80
Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
Cd80, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd80/CD80+Antibody%2C+anti-mouse%2C+REAfinity/pmc13694607-279-21-25
Average 94 stars, based on 1 article reviews
cd80 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
jurkat cells  (InvivoGen)
94
InvivoGen jurkat cells
Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
Jurkat Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd80/CTLA-4%2FCD80+Bio-IC/pm42546824-117-15-18
Average 94 stars, based on 1 article reviews
jurkat cells - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
cd80 fitc  (Elabscience Biotechnology)
94
Elabscience Biotechnology cd80 fitc
Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
Cd80 Fitc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd80/FITC+Anti-Mouse+CD80+Antibody/pm42909153-502-24-26
Average 94 stars, based on 1 article reviews
cd80 fitc - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
bv 2 activation  (ABclonal Biotechnology)
94
ABclonal Biotechnology bv 2 activation
Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
Bv 2 Activation, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd80/CD80+Rabbit+pAb/10__20517_slash_evcna__2026__91-105-2-17
Average 94 stars, based on 1 article reviews
bv 2 activation - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
cd80  (Novus Biologicals)
94
Novus Biologicals cd80
Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
Cd80, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd80/B7-1%2FCD80+Antibody+(2D10%2E4)+%5BAllophycocyanin%2FCy7%5D/pm42834086-288-31-33
Average 94 stars, based on 1 article reviews
cd80 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
anti cd80  (Elabscience Biotechnology)
94
Elabscience Biotechnology anti cd80
Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
Anti Cd80, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd80/FITC+Anti-Mouse+CD80+Antibody/pm42829139-144-17-18
Average 94 stars, based on 1 article reviews
anti cd80 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
pe anti mouse cd80  (Elabscience Biotechnology)
94
Elabscience Biotechnology pe anti mouse cd80
Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
Pe Anti Mouse Cd80, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd80/PE+Anti-Mouse+CD80+Antibody/10__1038_slash_s41467___026___77873___7-389-7-53
Average 94 stars, based on 1 article reviews
pe anti mouse cd80 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
cd80 pe  (Elabscience Biotechnology)
94
Elabscience Biotechnology cd80 pe
Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
Cd80 Pe, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd80/PE+Anti-Mouse+CD80+Antibody/10__1016_slash_j__cej__2026__182168-49-20-26
Average 94 stars, based on 1 article reviews
cd80 pe - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
anti cd80 fitc  (Elabscience Biotechnology)
94
Elabscience Biotechnology anti cd80 fitc
Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework
Anti Cd80 Fitc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd80/FITC+Anti-Mouse+CD80+Antibody/pm42551290-44-5-26
Average 94 stars, based on 1 article reviews
anti cd80 fitc - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework

Journal: Molecular Biomedicine

Article Title: EZH2 coordinates inflammatory and pain-associated pathways across joint compartments in osteoarthritis

doi: 10.1186/s43556-026-00643-w

Figure Lengend Snippet: Proposed model illustrating the effects of EZH2 inhibition across multiple joint compartments in osteoarthritis. In OA fibroblast-like synoviocytes (FLS), increased EZH2 and H3K27me3 levels were associated with inflammatory and catabolic responses, which were reduced by pharmacological EZH2 inhibition with EPZ-6438. In human OA FLS, EPZ-6438 decreased inflammatory, catabolic and pain-associated mediators, including IL1B, MMP13, NGF and NTN1, reduced LDHA expression and increased autophagy-associated responses. Proteomic and ChIP-seq analyses further identified inflammatory, metabolic and axon guidance-related pathways, including inflammation-dependent EZH2 recruitment at the PAX6 locus. EZH2 inhibition also reduced inflammatory activation of macrophages and osteoclastogenesis in OA-derived bone marrow cells. Collectively, these findings support a broader role for EZH2 in inflammatory, catabolic and osteoimmune responses across multiple OA-relevant cellular compartments. The identification of PAX6, NTN1 and axon guidance-related pathways highlights neuro-associated molecular programs that may be relevant to pain-associated responses, although their direct contribution to pain or sensory nerve remodeling was not assessed in this study. The reduced structural joint damage and pain-related behaviors observed following EZH2 inhibition in the MIA-induced OA model are consistent with this multicellular framework

Article Snippet: The following antibodies were used for immune cell characterization: CD11b (REA592 VioBlue, 130–113–810, Miltenyi Biotec), F4/80 (REA126 PE-Vio770, 130–118–459, Miltenyi Biotec), CD80 (REA983 APC-Vio770, 130–116–463, Miltenyi Biotec), CD86 (REA1190 PE, 130–122–129, Miltenyi Biotec), MHC-II (REA813 FITC, 130–112–386, Miltenyi Biotec), CD38 (REA616 PerCP-Vio700, 130–109–260, Miltenyi Biotec), and iNOS (REA982 APC, 130–116–423, Miltenyi Biotec).

Techniques: Inhibition, Expressing, ChIP-sequencing, Activation Assay, Derivative Assay